Testing for Anti-HPA-1a in Pregnant Patients
Testing for anti-HPA-1a antibodies is indicated in pregnant patients when: (1) a previous child had neonatal thrombocytopenia (platelet count <100 × 10⁹/L) without alternative cause, (2) there was unexplained fetal intracranial hemorrhage in a prior pregnancy, or (3) the current pregnancy shows unexplained fetal intracranial hemorrhage. 1
Clinical Indications for Testing
Index (First Affected) Pregnancy
The 2018 ISTH guidelines establish clear diagnostic criteria for when FNAIT should be suspected and testing initiated 1:
- Neonatal platelet count below 100 × 10⁹/L at birth or within 7 days postpartum, with no alternative explanation
- Fetal intracranial hemorrhage occurring without anatomical defects or prematurity
Critical caveat: Before pursuing FNAIT testing, exclude common causes of thrombocytopenia including hypoxia, infection, and other maternal conditions 1. Most affected infants will have platelet counts <50 × 10⁹/L, though milder cases (particularly with anti-HPA-5b antibodies) can occur 1.
Subsequent Pregnancies
In women with a previously affected pregnancy, testing should be performed early in the current pregnancy to guide antenatal management and assess fetal risk 1.
Important Clinical Context
When NOT to Test
The guidelines explicitly state there is no confirmed association between FNAIT and isolated fetal brain anomalies such as ventriculomegaly or brain cysts 1. Testing based solely on these findings is not indicated, as the frequency of positive serology in isolated intracranial hemorrhage is low 1.
Testing Algorithm
Complete FNAIT workup includes 1:
- HPA genotyping: Mother, neonate (preferred), or father
- Maternal serum antibody testing: Must use serum (not EDTA plasma, which reduces sensitivity) 1
- Crossmatch with paternal platelets
- Panel testing: HPA-1, -2, -3, -4, -5, -6, -9, and -15 alleles 1
Two different serological methods should be used to ensure concordance, such as MAIPA assay combined with bead-based multiplex assays or flow-based assays 1.
Critical Pitfalls to Avoid
Timing of Antibody Detection
Delayed alloantibodies (anti-HPA-1, -3, -5) may appear several weeks after birth and be missed in immediate perinatal testing 1. When HPA-1, -3, or -5 incompatibility is identified but initial antibody testing is negative, repeat maternal antibody testing 2-8 weeks postpartum 1.
Sample Type Matters
Never use EDTA plasma for antibody detection - it significantly reduces sensitivity of the MAIPA assay for HPA-1a antibodies 1. Maternal antibody testing requires serum samples.
Risk Stratification
Recent research demonstrates that approximately 90% of HPA-1a-immunized women are HLA-DRB3*01:01 positive 2, 3, 4. HPA-1bb women carrying this HLA type are at greatest risk of forming clinically significant anti-HPA-1a antibodies 2.
The maternal antibody level correlates with disease severity, with levels >3.0 IU/mL having 93% sensitivity and 63% specificity for predicting neonatal thrombocytopenia 5, 4. However, antibody levels alone do not reliably predict intracranial hemorrhage risk 2, 5, as antibody structural features (particularly Fc fucosylation and galactosylation) and Fab-mediated integrin blockade contribute significantly to disease severity 2, 6.
Population Screening Context
While not standard practice, prospective screening studies show that approximately 2.4-2.5% of pregnant women are HPA-1a negative, and among these, 8-9% develop anti-HPA-1a antibodies 3, 7. The incidence of severe clinically detectable bleeding is estimated at 11 per 10,000 HPA-1a-negative pregnancies 3. Primary immunization most commonly occurs at delivery rather than during the first pregnancy 4.